NUFOX + EGFR inhibitor

NUFOX + EGFR inhibitor is a combination therapy consisting of the chemotherapy regimen "NUFOX" and an epidermal growth factor receptor (EGFR) inhibitor. The "NUFOX" regimen is not a standard, widely recognized chemotherapy protocol; it may be a variant or regional naming for regimens similar to FOLFOX (which includes oxaliplatin, fluorouracil, and leucovorin), but this cannot be confirmed from available data. EGFR inhibitors are targeted therapies that block the activity of the epidermal growth factor receptor, which is often overexpressed or mutated in various cancers. These inhibitors can be small molecule tyrosine kinase inhibitors (such as erlotinib, gefitinib, osimertinib) or monoclonal antibodies (such as cetuximab or panitumumab). The combination aims to enhance anti-tumor efficacy by pairing cytotoxic chemotherapy with targeted inhibition of cancer cell signaling pathways involved in proliferation and survival[1][2][3][6].